Glaxo Lotronex
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In response to "many letters" about the company's Nov. 28 withdrawal of irritable bowel syndrome drug alosetron, FDA has drafted a letter to consumers saying that it "is ready to work with Glaxo Wellcome, as with any sponsor, to develop risk management plans to ensure appropriate patient access to medically important, effective drugs." The Dec. 18 letter, signed by CDER Director Janet Woodcock, MD, is another attempt to explain FDA's risk management concept to the public. Glaxo maintains that it had no choice but to withdraw the drug in the face of what it calls FDA's overly restrictive risk management proposa
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.